LifeStance Health Group, Inc.

What they do

LifeStance employs licensed mental health clinicians through its subsidiaries and supported practices across 33 states and treats patients in person at centers or virtually through its online platform. Its clinicians provide psychiatric evaluation and treatment, psychological and neuropsychological testing, and individual, family and group therapy for conditions including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders and PTSD. The company contracts in-network with commercial and government payors so patients can use their insurance benefits, and it works with primary care and specialist physicians as a referral channel.

Revenue drivers

• Outpatient visit volume — Revenue comes primarily from billed clinical visits; in 2025 clinicians treated over 1.0 million unique patients through approximately 9.0 million visits, and Q2 2026 visit volumes rose 19% to 2.6 million.
• Commercial and government payor reimbursement — The company earns in-network reimbursement from payors; two payors individually exceeded 10% of 2025 total revenue—UnitedHealthcare at 14% and Elevance Health at 15%.
• Clinician headcount and productivity — Growth is driven by adding clinicians and raising revenue per visit; the clinician base grew 11% year over year to 8,542 as of June 30, 2026, a sequential net increase of 193 in Q2.
• Multidisciplinary service mix — Services span psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy, delivered in person or virtually.

Recent performance

Q2 2026 revenue was $435.4 million, up 26% from $345.3 million a year earlier. Income from operations was $30.7 million and net income was $23.6 million, compared with a net loss of $3.8 million in Q2 2025. Center Margin rose 41% to $153.0 million, or 35.2% of revenue, and Adjusted EBITDA rose 94% to $66.0 million, or 15.2% of revenue. Net cash provided by operations was $99.9 million in the quarter and $133.0 million for the first six months of 2026, and free cash flow was $87.9 million in Q2. The company ended the quarter with $225.9 million of cash and cash equivalents and $259.0 million of net long-term debt.

Strategy

LifeStance is pursuing organic growth by expanding center capacity and visits within existing centers, extending into new geographies, and broadening specialty capabilities. It emphasizes clinical excellence and measurable patient outcomes as points of differentiation, alongside a tech-enabled in-person and virtual delivery model. The company announced a $100 million share repurchase program in its August 6, 2026 earnings release. It also invests in payor engagement and maintains an employed-clinician model supported by centralized administrative infrastructure.

Risks

• Payor concentration — UnitedHealthcare and Elevance Health together represented 29% of 2025 total revenue, so changes in their reimbursement rates, coverage, or network status could disproportionately hurt results.
• Reimbursement rate pressure — Commercial payors could reduce reimbursement rates or decline to cover some or all services, and a majority of payor relationships operate across multiple independent regional contracts, creating repricing exposure.
• Insurance dependence — During 2025, 95% of patients were insured as of their latest visit, so lost in-network status or narrow-network exclusion would directly reduce the addressable patient base.
• Medicaid policy changes — The OBBBA enacted July 4, 2025 changes Medicaid renewal and eligibility rules, with most effective dates in 2027 and 2028; LifeStance serves Medicaid patients but states the changes are not expected to have a material impact.

Outlook

Management raised full-year 2026 guidance to revenue of $1.685 billion to $1.725 billion, Center Margin of $570 million to $594 million, and Adjusted EBITDA of $215 million to $235 million. For Q3 2026, the company expects revenue of $420 million to $440 million and Center Margin of $140 million to $152 million. CEO Dave Bourdon cited momentum and the opportunity to extend reach into new geographies and broaden specialty capabilities.